Publication

Familiar barriers still unresolved-a perspective on the Zika virus outbreak research response

ZIKAlliance Consortium, Feb-2019, In : Lancet Infectious Diseases. 19, 2, p. e59-e62 4 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

ZIKAlliance Consortium (2019). Familiar barriers still unresolved-a perspective on the Zika virus outbreak research response. Lancet Infectious Diseases, 19(2), e59-e62. https://doi.org/10.1016/S1473-3099(18)30497-3

Author

ZIKAlliance Consortium. / Familiar barriers still unresolved-a perspective on the Zika virus outbreak research response. In: Lancet Infectious Diseases. 2019 ; Vol. 19, No. 2. pp. e59-e62.

Harvard

ZIKAlliance Consortium 2019, 'Familiar barriers still unresolved-a perspective on the Zika virus outbreak research response', Lancet Infectious Diseases, vol. 19, no. 2, pp. e59-e62. https://doi.org/10.1016/S1473-3099(18)30497-3

Standard

Familiar barriers still unresolved-a perspective on the Zika virus outbreak research response. / ZIKAlliance Consortium.

In: Lancet Infectious Diseases, Vol. 19, No. 2, 02.2019, p. e59-e62.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

ZIKAlliance Consortium. Familiar barriers still unresolved-a perspective on the Zika virus outbreak research response. Lancet Infectious Diseases. 2019 Feb;19(2):e59-e62. https://doi.org/10.1016/S1473-3099(18)30497-3


BibTeX

@article{bbde5c5763f3471f8a72bc6b7f94095e,
title = "Familiar barriers still unresolved-a perspective on the Zika virus outbreak research response",
abstract = "Research is an important component of an effective response to the increasing frequency of widespread infectious disease outbreaks. In turn, the ability to do such studies relies on willingness of partners in different regions to collaborate and the capacity to mount a rapid research response. The EU-funded ZIKAlliance Consortium has initiated a multicountry epidemiological, clinical, and laboratory research agenda to determine the incidence, risk factors, and outcomes of Zika virus infection in pregnant women and their children. We reviewed the timeline of patient cohort initiation in relation to the Zika virus epidemic and mapped key events regarding funding, regulatory approvals, and site preparation during this timeline. We then assessed barriers and delays that the international research team experienced through a systematic telephone interview. We have identified three major bottlenecks in the implementation of a swift response: the absence of a timeline for the funding process, delays in regulatory and ethical approval, and the challenging logistics of laboratory support, including diagnostics. These bottlenecks illustrate the clear and urgent need for implementing a strong and permanent global emerging infectious diseases research capacity that has structured funding, enables long-term partnerships, and develops basic clinical and laboratorial research and a response infrastructure that is ready to deploy.",
author = "{ZIKAlliance Consortium} and Marion Koopmans and {de Lamballerie}, Xavier and Thomas Jaenisch and Adriana Tami",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2019",
month = "2",
doi = "10.1016/S1473-3099(18)30497-3",
language = "English",
volume = "19",
pages = "e59--e62",
journal = "Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "ELSEVIER SCI LTD",
number = "2",

}

RIS

TY - JOUR

T1 - Familiar barriers still unresolved-a perspective on the Zika virus outbreak research response

AU - ZIKAlliance Consortium

AU - Koopmans, Marion

AU - de Lamballerie, Xavier

AU - Jaenisch, Thomas

AU - Tami, Adriana

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2019/2

Y1 - 2019/2

N2 - Research is an important component of an effective response to the increasing frequency of widespread infectious disease outbreaks. In turn, the ability to do such studies relies on willingness of partners in different regions to collaborate and the capacity to mount a rapid research response. The EU-funded ZIKAlliance Consortium has initiated a multicountry epidemiological, clinical, and laboratory research agenda to determine the incidence, risk factors, and outcomes of Zika virus infection in pregnant women and their children. We reviewed the timeline of patient cohort initiation in relation to the Zika virus epidemic and mapped key events regarding funding, regulatory approvals, and site preparation during this timeline. We then assessed barriers and delays that the international research team experienced through a systematic telephone interview. We have identified three major bottlenecks in the implementation of a swift response: the absence of a timeline for the funding process, delays in regulatory and ethical approval, and the challenging logistics of laboratory support, including diagnostics. These bottlenecks illustrate the clear and urgent need for implementing a strong and permanent global emerging infectious diseases research capacity that has structured funding, enables long-term partnerships, and develops basic clinical and laboratorial research and a response infrastructure that is ready to deploy.

AB - Research is an important component of an effective response to the increasing frequency of widespread infectious disease outbreaks. In turn, the ability to do such studies relies on willingness of partners in different regions to collaborate and the capacity to mount a rapid research response. The EU-funded ZIKAlliance Consortium has initiated a multicountry epidemiological, clinical, and laboratory research agenda to determine the incidence, risk factors, and outcomes of Zika virus infection in pregnant women and their children. We reviewed the timeline of patient cohort initiation in relation to the Zika virus epidemic and mapped key events regarding funding, regulatory approvals, and site preparation during this timeline. We then assessed barriers and delays that the international research team experienced through a systematic telephone interview. We have identified three major bottlenecks in the implementation of a swift response: the absence of a timeline for the funding process, delays in regulatory and ethical approval, and the challenging logistics of laboratory support, including diagnostics. These bottlenecks illustrate the clear and urgent need for implementing a strong and permanent global emerging infectious diseases research capacity that has structured funding, enables long-term partnerships, and develops basic clinical and laboratorial research and a response infrastructure that is ready to deploy.

U2 - 10.1016/S1473-3099(18)30497-3

DO - 10.1016/S1473-3099(18)30497-3

M3 - Review article

VL - 19

SP - e59-e62

JO - Lancet Infectious Diseases

JF - Lancet Infectious Diseases

SN - 1473-3099

IS - 2

ER -

ID: 74393439